2.93
+0.05(+1.74%)
Currency In USD
| Previous Close | 2.88 |
| Open | 2.83 |
| Day High | 2.96 |
| Day Low | 2.82 |
| 52-Week High | 27 |
| 52-Week Low | 2.75 |
| Volume | 107,426 |
| Average Volume | 1.11M |
| Market Cap | 6.64M |
| PE | -0.1 |
| EPS | -28.75 |
| Moving Average 50 Days | 6.48 |
| Moving Average 200 Days | 6.47 |
| Change | 0.05 |
If you invested $1000 in Processa Pharmaceuticals, Inc. (PCSA) 10 years ago, it would be worth $52.32 as of January 05, 2026 at a share price of $2.93. Whereas If you bought $1000 worth of Processa Pharmaceuticals, Inc. (PCSA) shares 5 years ago, it would be worth $20.58 as of January 05, 2026 at a share price of $2.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
GlobeNewswire Inc.
Dec 17, 2025 1:00 PM GMT
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis in early 2026 VERO BEACH, Fla.,
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
GlobeNewswire Inc.
Nov 05, 2025 2:15 PM GMT
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today annou
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
GlobeNewswire Inc.
Aug 07, 2025 12:30 PM GMT
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured